Please assess the completion status of the following clinical trial:

Trial Title: Topical Use of Difinsa53™ to Prevent Radiation Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients 18 years and older~* Pathologic diagnosis of breast cancer requiring radiation therapy to whole breast~* Able to apply lotion to treatment area at least twice daily during radiation course~* All surgical sites healed~* No evidence of infection~* No history of sensitivity to any component in Aquaphor or Difensa53~Exclusion Criteria:~* Prior history of radiation therapy (RT) to that site~* Known dermatologic conditions affecting skin in radiation port~* Concurrent chemotherapy~* Skin infection in radiation port~* History of sensitivity to Aquaphor or Difensa53 component

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor

Based on this trial design, predict the completion outcome and termination type (if applicable).